[Hydrashift 2/4达雷妥尤单抗检测法在消除达雷妥尤单抗对血清免疫固定电泳干扰中的应用]
[Application of Hydrashift 2/4 daratumumab assay in eliminating interference of daratumumab on serum immunofixation electrophoresis].
作者信息
Xu S, Liu Y, Wen L, Zhao L, Deng X, Rong R, Lu J
机构信息
Department of Clinical Laboratory, Peking University People's Hospital, Beijing 100044, China.
Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):840-845. doi: 10.3760/cma.j.issn.0253-2727.2021.10.008.
To investigate the interference of daratumumab on immunofixation electrophoresis after treating plasma cell diseases and methods to eliminate the interference. Serum samples of eight patients with plasma cell diseases treated with daratumumab in Peking University People's Hospital from April 2020 to March 2021 were collected for standard immunofixation electrophoresis and Hydrashift 2/4 daratumumab assay. After treatment, 81.3% (13/16) of the samples showed drug-induced monoclonal antibodies (IgG-κ) . The samples without drug-induced monoclonal bands were related to individual differences, administration intervals, and immunoglobulin levels. Among the samples with IgG-κ monoclonal bands, 76.9% (10/13) could be directly identified as endogenous or exogenous monoclonal bands by immunofixation electrophoresis, and the others (3/13) could be identified by Hydrashift 2/4 daratumumab assay. Hydrashift 2/4 daratumumab assay can remove the band of daratumumab on the immunofixation electrophoresis and help with efficacy evaluation.
探讨达雷妥尤单抗治疗浆细胞疾病后对免疫固定电泳的干扰及消除干扰的方法。收集2020年4月至2021年3月在北京大学人民医院接受达雷妥尤单抗治疗的8例浆细胞疾病患者的血清样本，进行标准免疫固定电泳和Hydrashift 2/4达雷妥尤单抗检测。治疗后，81.3%（13/16）的样本出现药物诱导的单克隆抗体（IgG-κ）。无药物诱导单克隆条带的样本与个体差异、给药间隔和免疫球蛋白水平有关。在出现IgG-κ单克隆条带的样本中，76.9%（10/13）可通过免疫固定电泳直接鉴定为内源性或外源性单克隆条带，其余（3/13）可通过Hydrashift 2/4达雷妥尤单抗检测鉴定。Hydrashift 2/4达雷妥尤单抗检测可去除免疫固定电泳上的达雷妥尤单抗条带，有助于疗效评估。
Zotero 插件